Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
Study sponsor: Vir Biotechnology, Inc. · VIR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-07-19Actual
Enrollment · participants1065Actual
Source updated2024-03-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.